World Health Organization Treatment Guidelines for Drug-resistant Tuberculosis, 2016 Update

Overview

Journal Eur Respir J

Specialty Pulmonary Medicine

Date 2017 Mar 24

PMID 28331043

Citations 153

Authors

Dennis Falzon

Holger J Schunemann

Elizabeth Harausz

Lice Gonzalez-Angulo

Christian Lienhardt

Ernesto Jaramillo

Karin Weyer

Affiliations

Soon will be listed here.

Abstract

Antimicrobial resistance is a major global concern. Tuberculosis (TB) strains resistant to rifampicin and other TB medicines challenge patient survival and public health. The World Health Organization (WHO) has published treatment guidelines for drug-resistant TB since 1997 and last updated them in 2016 based on reviews of aggregated and individual patient data from published and unpublished studies. An international expert panel formulated recommendations following the GRADE approach. The new WHO guidelines recommend a standardised 9-12 months shorter treatment regimen as first choice in patients with multidrug- or rifampicin-resistant TB (MDR/RR-TB) strains not resistant to fluoroquinolones or second-line injectable agents; resistance to these two classes of core second-line medicines is rapidly detectable with molecular diagnostics also approved by WHO in 2016. The composition of longer regimens for patients ineligible for the shorter regimen was modified. A first-ever meta-analysis of individual paediatric patient data allowed treatment recommendations for childhood MDR/RR-TB to be made. Delamanid is now also recommended in patients aged 6-17 years. Partial lung resection is a recommended option in MDR/RR-TB care. The 2016 revision highlighted the continued shortage of high-quality evidence and implementation research, and reiterated the need for clinical trials and best-practice studies to improve MDR/RR-TB patient treatment outcomes and strengthen policy.

Citing Articles

Impact of rpoB gene mutations and Rifampicin-resistance levels on treatment outcomes in Rifampicin-resistant tuberculosis.

Vadakunnel M, Nehru V, Brammacharry U, Ramachandra V, Palavesam S, Muthukumar A BMC Infect Dis. 2025; 25(1):284.

PMID: 40016696 PMC: 11866845. DOI: 10.1186/s12879-025-10655-6.

Optimizing emergency response systems in urban health crises: A project management approach to public health preparedness and response.

Ongesa T, Ugwu O, Ugwu C, Alum E, Eze V, Basajja M Medicine (Baltimore). 2025; 104(3):e41279.

PMID: 39833043 PMC: 11749675. DOI: 10.1097/MD.0000000000041279.

Rifampicin and isoniazid resistance not promote fluoroquinolone resistance in Mycobacterium smegmatis.

Zhou Q, Pu N, Xu G, Liu H, Jia X, Wang X PLoS One. 2025; 20(1):e0315512.

PMID: 39746086 PMC: 11694965. DOI: 10.1371/journal.pone.0315512.

Antimicrobial Resistance Levels of Non-Tuberculous Bacteria Isolates from Sputum of TB Patients in Ghana.

Morgan P, Ntiamoah D, Asare P, Mintah I, Osei-Wusu S, Boadu A Infect Drug Resist. 2024; 17:5663-5673.

PMID: 39717061 PMC: 11664477. DOI: 10.2147/IDR.S483529.

Efficacy and safety profile of 2 line Anti TB drugs in DRTB patients in a tertiary care hospital of South Punjab.

Rizwan H, Atif M, Hussain M, Nazeer R Pak J Med Sci. 2024; 40(11):2665-2674.

PMID: 39634911 PMC: 11613365. DOI: 10.12669/pjms.40.11.8605.

References

Schunemann H, Wiercioch W, Etxeandia I, Falavigna M, Santesso N, Mustafa R . Guidelines 2.0: systematic development of a comprehensive checklist for a successful guideline enterprise. CMAJ. 2013; 186(3):E123-42. PMC: 3928232. DOI: 10.1503/cmaj.131237. View

Dye C, Williams B, Espinal M, Raviglione M . Erasing the world's slow stain: strategies to beat multidrug-resistant tuberculosis. Science. 2002; 295(5562):2042-6. DOI: 10.1126/science.1063814. View

Guyatt G, Oxman A, Vist G, Kunz R, Falck-Ytter Y, Alonso-Coello P . GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008; 336(7650):924-6. PMC: 2335261. DOI: 10.1136/bmj.39489.470347.AD. View

. Case definition for extensively drug-resistant tuberculosis. Wkly Epidemiol Rec. 2006; 81(42):408. View

Winters N, Butler-Laporte G, Menzies D . Efficacy and safety of World Health Organization group 5 drugs for multidrug-resistant tuberculosis treatment. Eur Respir J. 2015; 46(5):1461-70. DOI: 10.1183/13993003.00649-2015. View

Mitnick C, White R, Lu C, Rodriguez C, Bayona J, Becerra M . Multidrug-resistant tuberculosis treatment failure detection depends on monitoring interval and microbiological method. Eur Respir J. 2016; 48(4):1160-1170. PMC: 5045442. DOI: 10.1183/13993003.00462-2016. View

Zignol M, Dean A, Alikhanova N, Andres S, Cabibbe A, Cirillo D . Population-based resistance of Mycobacterium tuberculosis isolates to pyrazinamide and fluoroquinolones: results from a multicountry surveillance project. Lancet Infect Dis. 2016; 16(10):1185-1192. PMC: 5030278. DOI: 10.1016/S1473-3099(16)30190-6. View

Zignol M, Dean A, Falzon D, Van Gemert W, Wright A, Van Deun A . Twenty Years of Global Surveillance of Antituberculosis-Drug Resistance. N Engl J Med. 2016; 375(11):1081-9. DOI: 10.1056/NEJMsr1512438. View

Tang S, Yao L, Hao X, Zhang X, Liu G, Liu X . Efficacy, safety and tolerability of linezolid for the treatment of XDR-TB: a study in China. Eur Respir J. 2014; 45(1):161-70. DOI: 10.1183/09031936.00035114. View

10.

Guyatt G, Schunemann H, Djulbegovic B, Akl E . Guideline panels should not GRADE good practice statements. J Clin Epidemiol. 2015; 68(5):597-600. DOI: 10.1016/j.jclinepi.2014.12.011. View

11.

Harris R, Khan M, Martin L, Allen V, Moore D, Fielding K . The effect of surgery on the outcome of treatment for multidrug-resistant tuberculosis: a systematic review and meta-analysis. BMC Infect Dis. 2016; 16:262. PMC: 4901410. DOI: 10.1186/s12879-016-1585-0. View

12.

Van Deun A, Maug A, Salim M, Das P, Sarker M, Daru P . Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med. 2010; 182(5):684-92. DOI: 10.1164/rccm.201001-0077OC. View

13.

Tang S, Yao L, Hao X, Liu Y, Zeng L, Liu G . Clofazimine for the treatment of multidrug-resistant tuberculosis: prospective, multicenter, randomized controlled study in China. Clin Infect Dis. 2015; 60(9):1361-7. DOI: 10.1093/cid/civ027. View

14.

Aung K, Van Deun A, Declercq E, Sarker M, Das P, Hossain M . Successful '9-month Bangladesh regimen' for multidrug-resistant tuberculosis among over 500 consecutive patients. Int J Tuberc Lung Dis. 2014; 18(10):1180-7. DOI: 10.5588/ijtld.14.0100. View

15.

Wright A, Zignol M, Van Deun A, Falzon D, Gerdes S, Feldman K . Epidemiology of antituberculosis drug resistance 2002-07: an updated analysis of the Global Project on Anti-Tuberculosis Drug Resistance Surveillance. Lancet. 2009; 373(9678):1861-73. DOI: 10.1016/S0140-6736(09)60331-7. View

16.

Piubello A, Harouna S, Souleymane M, Boukary I, Morou S, Daouda M . High cure rate with standardised short-course multidrug-resistant tuberculosis treatment in Niger: no relapses. Int J Tuberc Lung Dis. 2014; 18(10):1188-94. DOI: 10.5588/ijtld.13.0075. View

17.

Nasser S, Cooke G, Kranzer K, Norris S, Olliaro P, Ford N . Strength of recommendations in WHO guidelines using GRADE was associated with uptake in national policy. J Clin Epidemiol. 2015; 68(6):703-7. DOI: 10.1016/j.jclinepi.2014.11.006. View

18.

Nunn A, Rusen I, Van Deun A, Torrea G, Phillips P, Chiang C . Evaluation of a standardized treatment regimen of anti-tuberculosis drugs for patients with multi-drug-resistant tuberculosis (STREAM): study protocol for a randomized controlled trial. Trials. 2014; 15:353. PMC: 4164715. DOI: 10.1186/1745-6215-15-353. View

19.

Mitnick C, Rodriguez C, Hatton M, Brigden G, Cobelens F, Grobusch M . Programmatic Management of Drug-Resistant Tuberculosis: An Updated Research Agenda. PLoS One. 2016; 11(5):e0155968. PMC: 4880345. DOI: 10.1371/journal.pone.0155968. View

20.

Falzon D, Jaramillo E, Schunemann H, Arentz M, Bauer M, Bayona J . WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J. 2011; 38(3):516-28. DOI: 10.1183/09031936.00073611. View